Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1048-1054

  Kohlhapp, Frederick J ^a   Kaufman, Howard L ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE R; TALIMOGENE LAHERPAREPVEC; TUMOR ANTIGEN; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE CHECKPOINT; CELL DISRUPTION; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE DELETION; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; VIRUS GENE; VIRUS REPLICATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SIMPLEXVIRUS; VIROLOGY;

ANTIGENS, NEOPLASM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MELANOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 84962217836     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2667     Document Type: Article

References (43)

1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642-62.
2. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-8.
3. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3: 745-50.
4. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte- macrophage colony-stimulating factor. Mol Ther 2000;2:324-9.
5. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999;18:6112-20.
6. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990;62:379-90.
7. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, et al. Impact of protein kinase PKRin cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006;70:1032-60.
8. Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X, Williams BR. Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA. J Biol Chem 1997;272:9510-6.
9. Colthurst DR, Campbell DG, Proud CG. Structure and regulation of eukaryotic initiation factor eIF-2. Sequence of the site in the alpha subunit phosphorylated by the haem-controlled repressor and by the doublestranded RNA-activated inhibitor. Eur J Biochem 1987;166:357-63.
10. Sudhakar A, Ramachandran A, Ghosh S,Hasnain SE, Kaufman RJ, Ramaiah KV. Phosphorylation of serine 51 in initiation factor 2 alpha (eIF2 alpha) promotes complex formation between eIF2 alpha(P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B. Biochemistry 2000;39:12929-38.
11. Majumdar R, Maitra U. Regulation of GTP hydrolysis prior to ribosomal AUG selection during eukaryotic translation initiation. EMBO J 2005; 24:3737-46.
12. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004;23:3180-8.
13. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.EMBO J 1998;17:3351-62.
14. Cuddington BP, Mossman KL. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity. J Virol 2014;88:6885-95.
15. Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC, et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006;80:1110-20.
16. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 1997;94:843-8.
17. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A 1995;92:10516-20.
18. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.
19. Taneja S, MacGregor J, Markus S, HaS, Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 2001;98:8804-8.
20. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vectorwith enhancedMHCclass I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001;98:6396-401.
21. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001;75:5189-96.
22. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996;15:4759-66.
23. He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, Roizman B. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997;71:6049-54.
24. Poppers J, Mulvey M, Khoo D, Mohr I. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000;74:11215-21.
25. Cassady KA, Gross M, Roizman B. The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 1998;72:8620-6.
26. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36-49.
27. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000; 85:720-5.
28. Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, et al. Downregulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 2010;127: 830-8.
29. Davis KL, Korom M, Morrison LA. Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response. Virology 2014;468-470:330-9.
30. Verpooten D, MaY, Hou S, Yan Z, He B. Control of TANK-binding kinase 1- mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem 2009;284:1097-105.
31. Ma Y, Jin H, Valyi-Nagy T, Cao Y, Yan Z, He B. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J Virol 2012;86:2188-96.
32. Tomazin R, van Schoot NE, Goldsmith K, Jugovic P, Sempe P, Fruh K, et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 1998;72:2560-3.
33. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-5.
34. Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;2:11.
35. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17:718-30.
36. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
37. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47.
38. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71.
39. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18:1614-21.
40. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
41. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
42. Puzanov I MM, Andtbacka RH, Minor DR, Hamid O, Li A, Chou J, Kaufman HL. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 33, 2015.
43. Wisher M. Biosafety and product release testing issues relevant to replication- competent oncolytic viruses. Cancer Gene Ther 2002;9:1056-61.